In the T1D cohort, 36.7% received at least 1 metformin prescription (versus 88.6% in the T2D cohort), and 16.7% received a glucose-lowering medication prescription other than insulin and metformin (versus 75.7% in the T2D cohort). The gene discussed is INS; the disease is type 2 diabetes mellitus.